Brief: PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from EMA
28/11/2017 13:30
Nov 28 (Reuters) - PhaseRx Inc PZRX.O :
* PHASERX RECEIVES POSITIVE OPINION FOR ORPHAN DRUG
DESIGNATION
FOR PRX-ASL FROM EUROPEAN MEDICINES AGENCY
Source text for Eikon: ID:nPnxWBCwa
Further company coverage: PZRX.O
((Bangalore.newsroom@thomsonreuters.com;;))
Recent news on PZ Wind Down
See all newsBrief: Phaserx, Roivant Enter Into Asset Purchase Agreement
Brief: Phaserx Says Auction For Nearly All Of Co's Assets Was Held, But Did Not Conclude
Brief: Phaserx Revokes Proposed Distribution Record Date
Brief: PhaseRx Receives Decision From Nasdaq Hearings Panel For Continued Listing Of Shares
Brief: Phaserx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding